Bjoern O Schelter Selected Research

hydromethylthionine

1/2021	Long-Term Hydromethylthionine Treatment Is Associated with Delayed Clinical Onset and Slowing of Cerebral Atrophy in a Pre-Symptomatic P301S MAPT Mutation Carrier.
1/2020	Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.
1/2019	Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer's Disease.
1/2018	Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bjoern O Schelter Research Topics

Disease

4	Atrophy 01/2021 - 01/2018
3	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 12/2016
2	Frontotemporal Dementia (Semantic Dementia) 01/2021 - 01/2020
1	Cognitive Dysfunction 01/2019

Drug/Important Bio-Agent (IBA)

4	hydromethylthionineIBA 01/2021 - 01/2018
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2018
1	Methylene Blue (Methylthioninium Chloride)FDA Link 12/2016

Therapy/Procedure

2	Therapeutics 01/2019 - 12/2016
2	Activities of Daily Living (ADL) 01/2018 - 12/2016